MaxCyte, Inc. (MXCT) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

17/25

Growth 3 Margin 2 Expansion 5 Platform 4 Financial 3

latest quarter score

Earnings Reports

17
MaxCyte (MXCT) Q2 2026: $7.3M Revenue Reflects Stabilization with Genentech Deal Signaling Platform Expansion
August 13, 2026
12
MaxSight (MXCT) Q1 2026: OpEx Drops $7M, Unlocking Cash Burn Flexibility Amid SPL Portfolio Stability
May 13, 2026
11
MaxSight (MXCT) Q4 2025: $4M SPL Headwind Reshapes 2026 Base, DTX Launch Targets New Growth
March 25, 2026
17
MaxCyte (MXCT) Q3 2025: Restructuring Delivers $17M Cost Savings as SPL Pipeline Stays Resilient
November 13, 2025
14
MaxSight (MXCT) Q2 2025: Core Revenue Guidance Cut by $5M as Customer Consolidations Hit Outlook
August 06, 2025
25
MaxCyte (MXCT) Q1 2025: SPL Revenue Hits $2.1M as SecureDx Integration Expands TAM
July 04, 2025
21
MaxCyte (MXCT) Q4 2024: Core Revenue Growth of 20% Highlights Resilience Amid SPL Milestone Lull
March 11, 2025

Browse all companies